Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.

In this study, ritlecitinib 50-mg showed clinically meaningful efficacy, with improvements in the Severity of Alopecia Tool score observed in patients with alopecia areata over a 3-year period, demonstrating long-term benefit in both clinician- and patient-reported outcomes.

This study reviewed therapies for alopecia areata and suggests that Janus kinase inhibitors, such as baricitinib and upadacitinib, show promise in treating both alopecia areata and associated immune-mediated inflammatory diseases.

This study retrospectively evaluated the effectiveness of off-label baricitinib in children with severe alopecia areata and found that 50% achieved treatment goals, though psychological effects were noted and laboratory abnormalities occurred in 42.86% of patients.

This study found that patients with alopecia areata had similar total health care costs as those with atopic dermatitis, despite having fewer comorbidities and prescription medications overall.

In this study, 40.9% of patients taking 4 mg baricitinib and 21.2% taking 2 mg achieved significant hair regrowth over 52 weeks, indicating potential long-term benefits for adults with severe alopecia areata without introducing new safety concerns.

In this study, researchers found that patients with severe alopecia areata show varied regrowth timelines with baricitinib, and those with the most severe cases may still experience delayed but eventual improvement.

In a real-world study, baricitinib was effective for scalp, eyebrow, and eyelash regrowth in patients with alopecia areata, showing clinically meaningful improvements as early as 3 months and increasing up to 12 months; satisfaction and perceived improvement were also high among participants.

In this phase 3 trial analysis, baricitinib improved scalp hair growth in adults with severe alopecia areata, with a faster and higher response in those receiving 4 mg compared to 2 mg, but response varied with severity at baseline and continued through week 52.

This systematic review observed that a significant number of COVID-19 patients report long-term symptoms, including neurologic complaints and chronic fatigue, highlighting the presence of "post-COVID syndrome.

This review highlights that long-term health consequences of COVID-19, affecting multiple body systems, persist after acute infection, necessitating a comprehensive management approach that includes interdisciplinary care and lifestyle interventions to mitigate long-term damage.

This review examines biological reasons for sex-based differences in COVID-19 outcomes, noting that females exhibit stronger immune responses, potentially explaining lower severity and mortality compared to males.

This review observes higher ACE2 expression in myocardial and lung tissues of heart failure and COPD patients but finds no link between RAAS inhibitors and COVID-19 severity.

In this study, researchers developed a biomimetic anti-inflammatory nanosystem (MM-CEP/NLCs) that significantly reduced the severity of acute lung injury in vivo by targeting and accumulating in lung inflammation sites, showcasing its potential for treating inflammation.

This case study highlights that even short-term use of hydroxychloroquine for COVID-19 can potentially lead to acute generalized exanthematous pustulosis as an adverse effect.

This review discusses multisystem inflammatory syndrome in adults (MIS-A) related to SARS-CoV2 and outlines the existing knowledge and unanswered questions, reporting no new clinical results.

This review explores the molecular mechanisms and potential roles of nitric oxide in COVID-19 therapy, but provides no new clinical results.

In this study, an immortalized MSC line from human adipose tissue showed potential for applications in regenerative medicine and inflammatory diseases through production of active factors, demonstrated in vitro.

This study reported that COVID-19 skin manifestations, such as exanthema and chilblains, varied in timing but resolved positively with proper treatment.

This review outlines the urgent need for effective therapeutic interventions against coronaviruses, as current vaccines are challenged by virus mutations, and emphasizes developing safe, affordable, and broad-spectrum antivirals for both human and porcine coronaviruses.

Mesenchymal stromal cell therapies show promise for treating various diseases but need more research and standardization.

This study found that erythrocyte-anchored CPA-encapsulated nanoparticles improved the delivery and accumulation of Cepharanthine in the lungs, enhancing its effectiveness in treating acute lung injury by reducing inflammatory responses.

This study found that a notable percentage of COVID-19 patients experienced post-infection telogen effluvium, although no significant associations with infection-related factors were identified.

This systematic review found that antiandrogens do not appear to protect against SARS-CoV-2 infection or reduce COVID-19 severity, suggesting their use is not advisable for COVID-19 treatment.

This study observed a high prevalence of post-COVID-19 symptoms, including exertional dyspnea, cough, fatigue, and myalgia, among patients attending a post-COVID clinic in Southern India, with no significant symptom differences based on hospitalization during acute COVID-19.

This review highlights recent insights into using antiandrogens as preventive and therapeutic measures against COVID-19, emphasizing their role in blocking viral infection by modulating androgen-mediated host protease TMPRSS2 and cell entry protein ACE2, with varying success in clinical trials.

This study found histopathological evidence of hypertrophy in nerve endings that may explain the cutaneous neurosensory symptoms in some long COVID-19 patients.

This study found that combining ISX-9 with mesenchymal stem cells enhanced their ability to reduce inflammation and repair lung damage in an acute lung injury model compared to using the cells alone.

This study suggests that the Gabrin sign and hypertension in male patients are associated with a worse prognosis for COVID-19.

This study examined the current clinical practices for diagnosing and managing alopecia areata in Poland, finding that patient care is inadequate and falls short in using validated severity tools and providing access to advanced therapies despite the availability of new medications like Janus kinase inhibitors.